DUBLIN— Allergan plc (NYSE: AGN) this week reported financial results showing adjusted revenue of $3.9 billion in the fourth quarter, an increase of 7 percent, which the company attributed to “strong performance” from its facial aesthetics, eyecare and new product launches, among other factors.

In its eyecare segment, Allergan reported U.S. sales of $660.1 million in the fourth quarter, an increase of 6.8 percent. The company noted that U.S. sales of its leading eyecare treatment Restasis rose 13 percent to $393.1 million, “driven by demand and pricing,” in the quarter.

For the full year 2016, Allergan reported revenue of $14.57 billion, a 15 percent increase compared with the year-ago period. In the 12 months ending December 2016, Allergan reported overall sales in its eyecare segment of $2,437.7 million, an increase of 33 percent over the prior fiscal year.

“2016 was a year of transformation for Allergan,” Brent Saunders, chairman and chief executive officer, said in the statement. “We are now a branded biopharmaceutical leader, focused on delivering sustainable revenue growth, advancing our pipeline, maintaining industry leading margins and allocating capital to maximize shareholder return.”

Additionally in the U.S. eyecare segment, Allergan reported that its glaucoma franchise in the fourth quarter “experienced a modest decline,” with Alphagan/Combigan net revenues of $102.3 million, an increase of 2 percent versus prior-year results, which were offset by Lumigan net revenues declining 9 percent as a result of “trade buying patterns.”

Sales of Ozurdex were “strong at $22.6 million, up 18 percent versus prior year quarter driven by continued strong demand from the diabetic macular edema indication.”

Allergan also reported a fourth-quarter adjusted loss from continuing operations of $900.0 million and non-GAAP adjusted operating income from continuing operations of $1.87 billion in the quarter.

GAAP operating loss from continuing operations for the full year 2016 was $1.8 billion, a decrease in losses of 41.7 percent versus prior year primarily due to the fact that 2015 included the impact of selling through acquired inventory, higher acquisition related stock compensation expense and higher restructuring costs all in connection with the Allergan acquisition. Non-GAAP adjusted operating income from continuing operations for the full year 2016 was $7.25 billion, an increase of 7 percent versus prior year.

Saunders added, “We have taken bold actions to address issues impacting our industry and society. We are committed to our Social Contract with Patients, and our recent pricing actions are aligned with its principles.

"In November, we announced enhancements to our Patient Assistance Program (PAP) that position Allergan among industry leaders in providing free medicines for those who cannot afford our treatments. These commitments are important to the long-term stability of our company, but most importantly, they help the people who count on us to find and provide treatments for their most pressing medical needs.”